Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates
Shweta Singh(CytomX Therapeutics (United States)), Michael Kavanaugh(Naval Medical Center San Diego), Amy DuPage(CytomX Therapeutics (United States)), Michael Krimm(CytomX Therapeutics (United States)), Laura Serwer(CytomX Therapeutics (United States)), Matthew M. Ravn(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Shanti Duvur(CytomX Therapeutics (United States)), Ken Wong(CytomX Therapeutics (United States)), Susan E. Morgan-Lappe(Abbott Fund), Yuanhui Huang(Sinovac Biotech), Shouchun Liu(Lanzhou University of Technology), Rob Leanna(AbbVie (United States)), Sarah Patrick(CytomX Therapeutics (United States)), Sridhar Viswanathan(CytomX Therapeutics (United States)), Eric Ureno(CytomX Therapeutics (United States)), Adam M. Miller(Cornell University), Claus Krebber(CytomX Therapeutics (United States)), Ilaria Badagnani(AbbVie (United States)), Tracy Henriques(AbbVie (United States)), Niharika Chauhan(AbbVie (United States)), Jennifer Richardson(Interdisciplinary Dental Education Academy), Andrew Jang(CytomX Therapeutics (United States))
Cited by 5
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
Integrin cytoplasmic domain-binding proteins
|Journal of Cell Science|2000|571
Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
|Cancer Research|2007|302
Cues, context, and long-term memory: the role of the retrosplenial cortex in spatial cognition
|Frontiers in Human Neuroscience|2014|195
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
|Molecular Cancer Therapeutics|2016|185